UiPath (NYSE:PATH) Trading Down 0.4%

UiPath Inc. (NYSE:PATH - Get Free Report)'s share price dropped 0.4% during mid-day trading on Wednesday . The company traded as low as $19.15 and last traded at $19.41. Approximately 7,327,104 shares changed hands during trading, an increase of 21% from the average daily volume of 6,060,729 shares. The stock had previously closed at $19.48.

Wall Street Analyst Weigh In

PATH has been the topic of a number of research analyst reports. Wells Fargo & Company increased their price target on UiPath from $24.00 to $25.00 and gave the stock an "equal weight" rating in a report on Thursday, March 14th. Bank of America upped their target price on UiPath from $26.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 14th. KeyCorp assumed coverage on UiPath in a research report on Monday, April 8th. They set an "overweight" rating and a $27.00 target price on the stock. Truist Financial reaffirmed a "buy" rating and set a $32.00 target price on shares of UiPath in a research report on Wednesday, March 20th. Finally, Evercore ISI upped their target price on UiPath from $24.00 to $27.00 and gave the stock an "in-line" rating in a research report on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, UiPath has an average rating of "Moderate Buy" and a consensus price target of $27.41.

UiPath Trading Down 1.5 %

The stock has a market capitalization of $10.88 billion, a PE ratio of -112.46 and a beta of 0.96. The firm has a 50-day moving average price of $23.07 and a 200-day moving average price of $21.46.

UiPath (NYSE:PATH - Get Free Report) last announced its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The firm had revenue of $405.25 million during the quarter, compared to analyst estimates of $383.32 million. Sell-side analysts expect that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Insider Activity at UiPath

In related news, CFO Ashim Gupta sold 16,000 shares of the business's stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the sale, the chief financial officer now directly owns 87,505 shares in the company, valued at approximately $1,998,614.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have sold 72,000 shares of company stock worth $1,591,360. Company insiders own 31.03% of the company's stock.

Institutional Investors Weigh In On UiPath

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PATH. Intech Investment Management LLC grew its holdings in UiPath by 3.1% during the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company's stock valued at $356,000 after buying an additional 426 shares in the last quarter. 180 Wealth Advisors LLC grew its holdings in UiPath by 0.3% during the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company's stock valued at $4,497,000 after buying an additional 492 shares in the last quarter. Bleakley Financial Group LLC grew its holdings in shares of UiPath by 4.9% during the fourth quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company's stock worth $315,000 after purchasing an additional 598 shares in the last quarter. Simplicity Solutions LLC grew its holdings in shares of UiPath by 4.9% during the fourth quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company's stock worth $315,000 after purchasing an additional 598 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of UiPath by 40.2% during the first quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company's stock worth $50,000 after purchasing an additional 632 shares in the last quarter. 62.50% of the stock is currently owned by institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.